Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD20 monoclonal antibody PRO131921

A third-generation, humanized monoclonal antibody directed against human CD20 with potential antineoplastic activity. Anti-CD20 monoclonal antibody PRO131921 specifically binds to the B cell-specific cell surface antigen CD20. This may result in the induction of a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein which is exclusively expressed on B cells during most stages of B cell development and which is often overexpressed in B-cell malignancies.
Code name:PRO131921
Search NCI's Drug Dictionary